News – Page 1107 – Endpoints News

Tetraphase lines up a new FDA pitch for antibiotic after it comes through in latest PhIII

8 years ago

GSK CEO Walmsley is reorganizing R&D, dropping drugs and adding a new focus on cancer research

8 years ago

British billionaire Jim Mellon and high-profile partners roll the dice on an anti-aging upstart

8 years ago

Gottlieb to delay issuing layoff notices and reassures FDA staff that Congress will reauthorize user fees

8 years ago

Canaan reels in a jumbo $800M fund with a big focus on a new wave of biotech startups

8 years ago

Sarepta raising $325M; Astellas joins the big migration to Cambridge, MA

8 years ago

Neuralstem’s lead drug crumbles in PhII, adding to a litany of failures for depression drugs and blasting shares

8 years ago

Riders on the storm: VenatoRx bags a $42M round to back antibiotics pipeline

8 years ago

Biogen lays out a plan to “streamline” ops, add $400M to fund neurosciences R&D, new deals

8 years ago

Restructuring the pipeline, Eli Lilly says a baricitinib comeback in rheumatoid arthritis could take years

8 years ago

Lilly, J&J, AbbVie and WuXi help seed a regenerative medicine upstart

8 years ago

Novavax makes a case for a do-over on its failed RSV vaccine — but it's an uphill climb

8 years ago

Trading places with Bristol-Myers, Merck hit with another late-stage setback on checkpoint star Keytruda

8 years ago

Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta

8 years ago

Troubled Teva brings out the ax as it cuts deep into its Israeli pharma group

8 years ago

Gilead details its case for a new HIV flagship triple, with megablockbuster potential

8 years ago

Another micro-cap biotech has flunked a pivotal test for a regenerative cell therapy

8 years ago

Backed by partners at Pfizer, eFFECTOR brings its VC total to $150M as PhII cancer trial looms

8 years ago

Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar

8 years ago

Mitsubishi Tanabe bags NeuroDerm and its PhIII Parkinson’s program for $1.1B

8 years ago

Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug

8 years ago

An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business

8 years ago

Takeda explores computational chemistry leads from Schrödinger in $170M-plus pact; Aeterna Zentaris boots CEO, ...

8 years ago

Nektar’s pitch on early cancer drug OK runs into a regulatory brick wall

8 years ago

First page Previous page 1104 1105 110611071108 1109 1110 Next page Last page